Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OC-103
- Development stage
- Preclinical
- Lead developer
- Viatris
- Modality
- Gene Therapies
- Administration
- Ophthalmic, Injection
01
Overview
OC-103 is a gene therapy candidate developed by Oyster Point Pharmaceuticals (now part of Viatris) for ophthalmic indications, specifically for the treatment of keratoconjunctivitis. The therapy utilizes an adeno-associated virus (AAV) vector to deliver the gene encoding diamine oxidase (DAO) to ocular tissues, aiming to address ocular inflammation associated with keratoconjunctivitis through gene transference. The mechanism is gene transfer, introducing the DAO gene into cells to support an anti-inflammatory effect. The drug has not yet received orphan status and is classified under eye disorder therapies and gene therapies. Preclinical development status as of January 2023[3].
- Other names
- OC 103OC103OC-103OC-103 - Oyster Point PharmaceuticalsOC103 - Oyster Point PharmaceuticalsOC 103 - Oyster Point Pharmaceuticals
02
Targets
DAO (D-amino-acid oxidase)
Beyond the preview
Go deeper on OC-103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OC-103.